Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799643 · ClinicalTrials.gov registry record · Phase 2
Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II
A Phase 2 study, sponsored by Joslin Diabetes Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 638
- Enrollment target
NCT00799643: Completed Phase 2 study, sponsored by Joslin Diabetes Center.
NCT00799643 is a Phase 2 study that has completed, run by Joslin Diabetes Center. The registered enrollment target is 638 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (380% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00799643, a Phase 2 study, has completed, sponsored by Joslin Diabetes Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 638 participants
- Enrollment target
Study Summary
Growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study we will determine whether salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type 2 diabetes. The study will determine whether salicylates represent a new pharmacological option for diabetes management. The study is conducted in two stages. Enrollment in the first stage is complete. The primary objective of the first stage was to select a dose of salsalate that is both well-tolerated and demonstrates a trend toward improvement in glycemic control. The primary objective of Stage 2 of the study is to evaluate the effects of salsalate on blood sugar control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes (T2D); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and cardiac risk.
Primary Outcome
HbA1c (%, percentage of HbA1c) change from baseline.
Interventions
- DRUG Salsalate
- DRUG Salsalate Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 638 participants |
| Start Date | 2008-11 |
| Phase | Phase 2 |
What the finished NCT00799643 record still lists
NCT00799643 is an interventional study that assigns participants to a tested intervention. The registered 638 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (380% higher).
The record links to 0 conditions, and to 2 interventions - of which Salsalate is the first listed.
NCT00799643 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00799643 about?
NCT00799643 is a clinical study titled "Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II". Growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study we will determine whether salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effec...
What is the current status of trial NCT00799643?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 638 participants. The study started on 2008-11.
What interventions are being tested in trial NCT00799643?
The interventions under investigation include: Salsalate (DRUG), Salsalate Placebo (DRUG).
Who is sponsoring clinical trial NCT00799643?
This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00799643's enrollment target sits among peer trials
638 51st of 2000 higher than 1,950 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04339699 · 640 participants · NA
NobleStitch EL STITCH Trial is a PFO Comparative Trial
- NCT04979338 · 640 participants · Phase 3
Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries
- NCT05156398 · 640 participants · Phase 3
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- NCT05930483 · 640 participants · NA
Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia